Danish bio-flavour innovator EvodiaBio has successfully closed a new funding round raising €6 million. The investment was led by U.S.-based RA Capital, with participation from new international investors Wild Radicals and Francis Family Funds, alongside continued support from existing investor EIFO.
The capital injection is earmarked to accelerate the company’s commercial expansion across Europe, the United States, and Canada, while laying the groundwork for market entry into Asia.
Technology and Industrial Scale
EvodiaBio has developed a proprietary technology platform that enables the industrial-scale production of volatile aroma molecules. This biotech approach offers a sustainable alternative to traditional methods, specifically addressing the beer industry's reliance on hops—a raw material increasingly threatened by climate change.
The company has transitioned rapidly from a research project to industrial production in just three and a half years.
Camilla Kloss Fenneberg, CEO of EvodiaBio, outlined the company's trajectory:
"This investment puts us in a position to scale globally... within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the biotech industry. This investment enables us to accelerate global growth and realise our ambition of becoming a Danish unicorn in industrial biotech."
Commercial Traction and Partnerships
Since its commercial launch earlier this year, EvodiaBio has secured significant market validation:
Adoption: The technology is currently utilised in more than 70 commercial brews.
Pipeline: The company has over 10 active projects with top-40 breweries worldwide.
Distribution: Rapid market access is supported by established channel partnerships with industry giants Symrise and Lallemand.
Jarne Elleholm, Chairman of the Board, emphasised the de-risking of the business model:
"RA Capital’s investment... confirms that we have removed the key risks related to technology, production, and commercialisation. We have proven that the technology works, that customers are interested in the product, and that the business model has been profitable from day one."
Investor Sentiment
Lead investor RA Capital highlighted the rarity of EvodiaBio's operational maturity at this stage of funding.
Kyle Teamey, Managing Partner at RA Capital, commented:
"EvodiaBio has developed a technology platform that convincingly solves one of the most complex problems in the aroma and beverage industries: how to efficiently and sustainably produce natural aromas at an industrial scale... It is exceptional for a biotech company to already have in-house production, validated technology, strong commercial demand, and established distribution partners at this stage."
Future Roadmap
Beyond geographic expansion into Asia, the funding will support the application of EvodiaBio's technology into new verticals. The company plans to expand beyond beer into the broader beverage sector, wine, and the general aroma industry.
This latest round marks the company’s third in three years, bringing total funds raised to DKK 150 million.
EvodiaBio Secures €6m to Scale Sustainable Aroma Tech and Target Asian Market
News
December 22, 2025
Related news
Willie’s Remedy+ Secures $15M Series A to Drive National Retail Expansion for THC Beverages
.jpg)
The Marzetti Company Acquires Bachan’s for $400M to Expand Premium Sauce Portfolio
TrueStart Coffee Secures Series A Investment Led by Innocent Drinks Founders
